11:00 , Aug 21, 2019 |  BC Extra  |  Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
19:30 , Aug 7, 2019 |  BC Extra  |  Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
21:51 , Sep 14, 2018 |  BioCentury  |  Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
17:28 , Sep 14, 2018 |  BC Week In Review  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
13:08 , Sep 12, 2018 |  BC Extra  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
17:46 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and...
21:22 , Sep 6, 2018 |  BC Extra  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also...
02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...